M.L. MAKSIMOV^{1, 2, 3, 4}, A.A. ZVEGINTSEVA^1, 2, M.A. ISLAMOVA², T.YU. KULAGINA^1, 2

 ¹Republic Clinical Hospital of the Republic of Tatarstan, Kazan

² Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, , Kazan

³Kazan (Volga) Federal University, Kazan

⁴Russian National Research Medical University named after N.I. Pirogov, Moscow

  Contact details:

Maksimov M.L. — MD, Professor, Head of the Department of Clinical Pharmacology and Pharmacotherapy, Professor of the Department of Pharmacology of RNRMU named after N.I. Pirogov, Professor of the Department of Fundamentals of Clinical Medicine

Address: 36 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-916-1145955, e-mail: maksim_maksimov@mail.ru

 Today, over 182 mln people worldwide are infected with the new coronavirus infection and over 3 mln people have died of it. Quarantine measures cannot comprehensively prevent further spread of SARS-CoV-2, as they do not involve the inner mechanisms of antiviral protection; thus, it is necessary to consider other prophylactic methods of contamination and development of severe forms of COVID-19. Low levels of vitamin D in blood determine a more unfavorable course of the disease and are associated with a large number of lethal outcomes of COVID-19. Also, low levels of this vitamin correlate with higher vulnerability to SARS-CoV-2. Meta analysis of 25 randomized studies showed that intake of vitamin D reliably reduces the risk of ARVI contamination by 12% on average and also reduces the risk of repeated ARVI contamination in persons having at least one ARVI episode in a year. It is essential to use the available methods of COVID-19 prophylactics, one of which is adequate provision with vitamin D.

Key words: new coronavirus infection, vitamin D, prophylactics of COVID-19, ARVI, SARS-CoV-2, claciferol, calcitriol, immune response, antiviral immunity.

REFERENCES

1. Zella L.A. et al. Vitamin D-binding protein influences total circulating levels of 1, 25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology, 2008, vol. 149 (7), pp. 3656–3667.
2. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends in biochemical sciences, 2004, vol. 29 (12), pp. 664–673.
3. Rowling M.J. et al. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. The Journal of nutrition, 2006, vol. 136 (11), pp. 2754–2759.
4. Bikle D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chemistry & biology, 2014, vol. 21 (3), pp. 319–329.
5. Yoshida T., Fujimori T., Nabeshima Y. I. Mediation of unusually high concentrations of 1, 25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1α-hydroxylase gene. Endocrinology, 2002, vol. 143 (2), pp. 683–689.
6. Aranow C. Vitamin D and the immune system. Journal of investigative medicine, 2011, vol. 59 (6), pp. 881–886.
7. Cannell J.J. et al. Epidemic influenza and vitamin D. Epidemiology & Infection, 2006, vol. 134 (6), pp. 1129–1140.
8. Martineau A.R. et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ, 2017, vol. 356.
9. Ilie P.C., Stefanescu S., Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research, 2020, pp. 1–4.
10. Lips P. et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. European Journal of Endocrinology, 2019, vol. 180 (4), pp. 23–54.
11. Isaia G. et al. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporosis International, 2003, vol. 14 (7), pp. 577–582.
12. Maghbooli Z. et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PloS one, 2020, vol. 15 (9), p. e0239799.
13. D’Avolio Antonio et al. 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients, 2020, vol. 12 (5), pp. 1359.
14. Panagiotou G. et al. Low serum 25‐hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID‐19 are associated with greater disease severity. Clinical endocrinology, 2020.
15. Prietl B. et al. Vitamin D and immune function. Nutrients, 2013, vol. 5 (7), pp. 2502–2521.
16. Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology, 2020, p. 108427.
17. Vremennye metodicheskie rekomendatsii profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19) Versiya 8.1 (01.10.2020) [Interim guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) Version 8.1 (01.10.2020)], available at: https://minzdrav.gov.ru/ministry/med_covid19
18. Maksimov M.L. et al. Kliniko-farmakologicheskie aspekty vedeniya patsientov s koronavirusnoy infektsiey COVID-19: etiologiya, epidemiologiya, klinika, diagnostika, lechenie i profilaktika: uchebno-metodicheskoe posobie dlya meditsinskikh rabotnikov [Clinical and pharmacological aspects of the management of patients with coronavirus infection COVID-19: etiology, epidemiology, clinical picture, diagnosis, treatment and prevention: a training manual for medical workers]. Kazan: Redaktsionno-izdatel’skiy otdel KGMA, 2020. 64 p.
19. Gromova O.A., Torshin I.Yu., Gabdulina G.Kh. Pandemic COVID-19: protective roles of vitamin D. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya, 2020, vol. 13, no. 2, pp. 132–145.
20. Bastard P. et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020.
21. Zhou D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural & Molecular Biology, 2020, pp. 1–9.
22. Felsensteina S. et al. COVID-19: Immunology and treatment methods. Clinical Immunology, 2020, vol. 215, p. 108448 (in Russ.).
23. Diao B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology, 2020, vol. 11, p. 827.
24. Ismailova M.A., Maksimov M.L., Malykhina A.I., Kulagina L.Yu. Vitaminoterapiya i vitaminoprofilaktika: uchebnoe posobie po klinicheskoy farmakologii [Vitamin therapy and vitamin prophylaxis: a textbook on clinical pharmacology]. KGMA — filial FGBOU DPO RMANPO MZ RF. Kazan, 2020. 88 p.
25. Ismailova M.A., Maksimov M.L., Malykhina A.I., Kulagina L.Yu. Klinicheskaya farmakologiya vitaminov. Vitaminoprofilaktika i vitaminoterapiya u patsientov raznykh vozrastnykh grupp: uchebnoe posobie po klinicheskoy farmakologii [Clinical pharmacology of vitamins. Vitamin prophylaxis and vitamin therapy in patients of different age groups: a textbook on clinical pharmacology]. KGMA — filial FGBOU DPO RMANPO MZ RF. Kazan, 2020. 96 p.
26. Pigarova E.A. et al. Clinical guidelines of the Russian Association of Endocrinologists for the diagnosis, treatment and prevention of vitamin D deficiency in adults. Problemy endokrinologii, 2016, vol. 62, no. 4 (in Russ.).
27. Gromova O.A. et al. Vitamin D — smena paradigmy [Vitamin D — a paradigm shift]. Moscow: GEOTAR-Media, 2017. 568 p.
28. Stoffels K. et al. Immune regulation of 1α-hydroxylase in murine peritoneal macrophages: unravelling the IFNγ pathway. The Journal of steroid biochemistry and molecular biology, 2007, vol. 103 (3–5), pp. 567–571.
29. Bouillon R. et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocrine reviews, 2008, vol. 29 (6), pp. 726–776.
30. Povoroznyuk V.V. et al. The value of vitamin D in the pathogenesis of cardiovascular diseases. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2015, no. 2 (50) (in Russ.).
31. Kulikov V.A., Grebennikov I.N. The role of vitamins D and K in the development of vascular calcification and atherosclerosis. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta, 2012, vol. 11, no. 4 (in Russ.).
32. Yang J. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2020, vol. 94, pp. 91–95.
33. Madjid M. et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA cardiology, 2020.
34. Ma W.X., Ran X.W. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19. Sichuan da xuexuebao. Yi xue ban. Journal of Sichuan University. Medical Science Edition, 2020, Mar, vol. 51 (2), pp. 146–150. DOI: 10.12182/20200360606
35. World Health Organization et al. Nutritional rickets: a review of disease burden, causes, diagnosis, prevention and treatment, 2019.
36. Martineau A.R., Forouhi N.G. Vitamin D for COVID-19: a case to answer? The Lancet Diabetes & Endocrinology, 2020, vol. 8 (9), pp. 735–736.
37. Maylyan E.A. The influence of genetic polymorphisms of the genes of the vitamin D system on the serum level of 25 (OH) D (review). Vestnik Smolenskoy gosudarstvennoy meditsinskoy akademii, 2017, no. 1 (in Russ.), available at: https://cyberleninka.ru/article/n/vliyanie-geneticheskih-polimorfizmov-genov-sistemy-vitamina-d-na-syvorotochnyy-uroven-25-on-d-obzor
38. MR 2.3.1.2432–08 Normy fiziologicheskikh potrebnostey v energii i pishchevykh veshchestvakh dlya razlichnykh grupp naseleniya Rossiyskoy Federatsii [MR 2.3.1.2432–08 Norms of physiological requirements for energy and nutrients for various groups of the population of the Russian Federation].